XFOR (X4 Pharmaceuticals) Long-Term Debt: $76.52 Mil (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $4.02
! 6 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Long-Term Debt?

X4 Pharmaceuticals XFOR +0.37% 29 Long-Term Debt is $76.52 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 6 warning signs investors should review.

X4 Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $76.52 Mil.

X4 Pharmaceuticals's quarterly Long-Term Debt increased from Sep. 2025 ($76.06 Mil) to Dec. 2025 ($76.29 Mil) and increased from Dec. 2025 ($76.29 Mil) to Mar. 2026 ($76.52 Mil).

X4 Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 ($54.57 Mil) to Dec. 2024 ($75.43 Mil) and increased from Dec. 2024 ($75.43 Mil) to Dec. 2025 ($76.29 Mil).

X4 Pharmaceuticals  (NAS:XFOR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

X4 Pharmaceuticals Long-Term Debt Related Terms

X4 Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Long-Term Debt Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.14 32.30 54.57 75.43 76.29

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.63 75.84 76.06 76.29 76.52
XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $76.52 Mil mean?
X4 Pharmaceuticals (XFOR) has a Long-Term Debt of $76.52 Mil as of Mar. 2026.
Is X4 Pharmaceuticals' Long-Term Debt too high?
X4 Pharmaceuticals' current Long-Term Debt is $76.52 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Long-Term Debt compare to ZURA and LYEL?
X4 Pharmaceuticals' Long-Term Debt of $76.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. X4 Pharmaceuticals's current Long-Term Debt is $76.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Long-Term Debt of $76.52 Mil. The current Long-Term Debt is $76.52 Mil. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Long-Term Debt is $76.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.02
Price